India’s Big AI 'Garage' Ambition – Can It Get The Mechanics Running ?
Healthcare is one of the core areas targeted under India's National Strategy For Artificial Intelligence, which also seeks to position the country as the "AI Garage for 40% of the world." But does the ambitious plan put the cart before the horse in a country that still faces several fundamental challenges?
You may also be interested in...
Novartis CEO Vas Narasimhan outlines how the company is progressing data science and digital transformation across operations, including plans to use predictive analytics to forecast production supply chain runs. The Swiss firm is also monitoring the evolving coronavirus situation closely but has safety stocks for its key products and innovative medicine portfolio and is "okay" for now.
Cipla chairman underscores the potential and value of repurposing drugs for Indian researchers and pharma firms looking to build their R&D activities, amid signs of growing attention to the promising area globally.
Paul Hudson, CEO, Novartis Pharmaceuticals, was recently in India along with the executive leadership team of the Swiss multinational. In a wide-ranging exclusive interview with Scrip, he discussed Cosentyx’s edge over its competition, Entresto’s “incredibly bright future”, including in emerging markets like India, and why transparency on the scale of rebates in the US is "overdue."